[1] |
Butel MJ, Waligora-Dupriet AJ, Wydau-Dematteis S . The developing gut microbiota and its consequences for health[J]. J Dev Orig Health Dis, 2018,9(6):590-597. DOI: 10.1017/S2040174418000119.
|
[2] |
Oh TI, Lee JH, Kim S , et al. Fascaplysin sensitizes anti-cancer effects of drugs targeting AKT and AMPK[J]. Molecules, 2017, 23(1). pii: E42. DOI: 10.3390/molecules23010042.
|
[3] |
Wong SH, Kwong TNY, Wu CY , et al. Clinical applications of gut microbiota in cancer biology[J]. Semin Cancer Biol, 2019,55:28-36. DOI: 10.1016/j.semcancer.2018.05.003.
|
[4] |
Whisner CM, Athena Aktipis C . The role of the microbiome in cancer initiation and progression: how microbes and cancer cells utilize excess energy and promote one another's growth[J]. Curr Nutr Rep, 2019,8(1):42-51. DOI: 10.1007/s13668-019-0257-2.
|
[5] |
Scanu T, Spaapen RM, Bakker JM , et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma[J]. Cell Host Microbe, 2015,17(6):763-774. DOI: 10.1016/j.chom.2015.05.002.
|
[6] |
Mascitti M, Togni L, Troiano G , et al. Beyond head and neck cancer: the relationship between oral microbiota and tumour development in distant organs[J]. Front Cell Infect Microbiol, 2019,9:232. DOI: 10.3389/fcimb.2019.00232.
|
[7] |
Amrutkar M, Gladhaug IP . Pancreatic cancer chemoresistance to gemcitabine[J]. Cancers (Basel) , 2017, 9(11). pii: E157. DOI: 10.3390/cancers9110157.
|
[8] |
Ertz-Archambault N, Keim P, Von Hoff D . Microbiome and pancreatic cancer: a comprehensive topic review of literature[J]. World J Gastroenterol, 2017,23(10):1899-1908. DOI: 10.3748/wjg.v23.i10.1899.
|
[9] |
de Martel C, Ferlay J, Franceschi S , et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis[J]. Lancet Oncol, 2012,13(6):607-615. DOI: 10.1016/S1470-2045(12)70137-7.
|
[10] |
Torres PJ, Fletcher EM, Gibbons SM , et al. Characterization of the salivary microbiome in patients with pancreatic cancer[J]. PeerJ, 2015,3:e1373. DOI: 10.7717/peerj.1373.
|
[11] |
Wei MY, Shi S, Liang C , et al. The microbiota and microbiome in pancreatic cancer: more influential than expected[J]. Mol Cancer, 2019,18(1):97. DOI: 10.1186/s12943-019-1008-0.
|
[12] |
Vogtmann E, Goedert JJ . Epidemiologic studies of the human microbiome and cancer[J]. Br J Cancer, 2016,114(3):237-242. DOI: 10.1038/bjc.2015.465.
|
[13] |
Park JY, Forman D, Waskito LA , et al. Epidemiology of Helicobacter pylori and CagA-positive infections and global variations in gastric cance[J]. Toxins (Basel), 2018, 10(4). pii: E163. DOI: 10.3390/toxins10040163.
|
[14] |
Rajagopala SV, Vashee S, Oldfield LM , et al. The human microbiome and cancer[J]. Cancer Prev Res (Phila), 2017,10(4):226-234. DOI: 10.1158/1940-6207.CAPR-16-0249.
|
[15] |
Xiao M, Wang Y, Gao Y . Association between Helicobacter pylori infection and pancreatic cancer development: a meta-analysis[J]. PLoS One, 2013,8(9):e75559. DOI: 10.1371/journal.pone.0075559.
|
[16] |
Wang Y, Zhang FC, Wang YJ . Helicobacter pylori and pancreatic cancer risk: a meta-analysis based on 2 049 cases and 2 861 controls[J]. Asian Pac J Cancer Prev, 2014,15(11):4449-4454. DOI: 10.7314/apjcp.2014.15.11.4449-54.
|
[17] |
Chen J, Domingue JC, Sears CL . Microbiota dysbiosis in select human cancers: evidence of association and causality[J]. Semin Immunol, 2017,32:25-34. DOI: 10.1016/j.smim.2017.08.001.
|
[18] |
Huang J, Zagai U, Hallmans G , et al. Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: a nested case-control study[J]. Int J Cancer, 2017,140(8):1727-1735. DOI: 10.1002/ijc.30590.
|
[19] |
Gholizadeh P, Eslami H, Kafil HS . Carcinogenesis mechanisms of Fusobacterium nucleatum[J]. Biomed Pharmacother, 2017,89:918-925. DOI: 10.1016/j.biopha.2017.02.102.
|
[20] |
Mitsuhashi K, Nosho K, Sukawa Y , et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis[J]. Oncotarget, 2015,6(9):7209-7220. DOI: 10.18632/oncotarget.3109.
|
[21] |
Dickson I . Microbiome promotes pancreatic cancer[J]. Nat Rev Gastroenterol Hepatol, 2018,15(6):328. DOI: 10.1038/s41575-018-0013-x.
|
[22] |
Serra N, Di Carlo P, Gulotta G , et al. Bactibilia in women affected with diseases of the biliary tract and pancreas. A STROBE guidelines-adherent cross-sectional study in Southern Italy[J]. J Med Microbiol, 2018,67(8):1090-1095. DOI: 10.1099/jmm.0.000787.
|
[23] |
Olson SH, Satagopan J, Xu Y , et al. The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study[J]. Cancer Causes Control, 2017,28(9):959-969. DOI: 10.1007/s10552-017-0933-8.
|
[24] |
Geller LT, Barzily-Rokni M, Danino T , et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J]. Science, 2017,357(6356):1156-1160. DOI: 10.1126/science.aah5043.
|
[25] |
Woo BH, Kim DJ, Choi JI , et al. Oral cancer cells sustainedly infected with Porphyromonas gingivalis exhibit resistance to taxol and have higher metastatic potential[J]. Oncotarget, 2017,8(29):46981-46992. DOI: 10.18632/oncotarget.16550.
|
[26] |
Iida N, Dzutsev A, Stewart CA , et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J]. Science, 2013,342(6161):967-970. DOI: 10.1126/science.1240527.
|
[27] |
Gui QF, Lu HF, Zhang CX , et al. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model[J]. Genet Mol Res, 2015,14(2):5642-5651. DOI: 10.4238/2015.May.25.16.
|
[28] |
Wallace BD, Wang H, Lane KT , et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme[J]. Science, 2010,330(6005):831-835. DOI: 10.1126/science.1191175.
|
[29] |
Kaiser J, Couzin-Frankel J . Cancer immunotherapy sweeps nobel for medicine[J]. Science, 2018,362(6410):13. DOI: 10.1126/science.362.6410.13.
|
[30] |
Sivan A, Corrales L, Hubert N , et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy[J]. Science, 2015,350(6264):1084-1089. DOI: 10.1126/science.aac4255.
|
[31] |
Vetizou M, Pitt JM, Daillere R , et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J]. Science, 2015,350(6264):1079-1084. DOI: 10.1126/science.aad1329.
|
[32] |
Pushalkar S, Hundeyin M, Daley D , et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J]. Cancer Discov, 2018,8(4):403-416. DOI: 10.1158/2159-8290.CD-17-1134.
|
[33] |
Cengiz TB, Jarrar A, Power C , et al. Antimicrobial stewardship reduces surgical site infection rate, as well as number and severity of pancreatic fistulae after pancreatoduodenectomy[J]. Surg Infect (Larchmt), 2019. DOI: 10.1089/sur.2019.108.
|
[34] |
Maatman TK, Weber DJ, Qureshi B , et al. Does the microbiology of bactibilia drive postoperative complications after pancreatoduodenectomy?[J]. J Gastrointest Surg, 2019. DOI: 10.1007/s11605-019-04432-5.
|
[35] |
Ohgi K, Sugiura T, Yamamoto Y , et al. Bacterobilia may trigger the development and severity of pancreatic fistula after pancreatoduodenectomy[J]. Surgery, 2016,160(3):725-730. DOI: 10.1016/j.surg.2016.03.032.
|
[36] |
Sugiura T, Mizuno T, Okamura Y , et al. Impact of bacterial contamination of the abdominal cavity during pancreaticoduodenectomy on surgical-site infection[J]. Br J Surg, 2015,102(12):1561-1566. DOI: 10.1002/bjs.9899.
|
[37] |
Belmouhand M, Krohn PS, Svendsen LB , et al. The occurrence of enterococcus faecium and faecalis is significantly associated with anastomotic leakage after pancreaticoduodenectomy[J]. Scand J Surg, 2018,107(2):107-113. DOI: 10.1177/1457496917-731188.
|
[38] |
Yokoyama Y, Asahara T, Nomoto K , et al. Effects of synbiotics to prevent postoperative infectious complications in highly invasive abdominal surgery [J]. Ann Nutr Metab, 2017, Suppl 1: 23-20. DOI: 10.1159/000479920.
|
[39] |
Mima K, Nakagawa S, Sawayama H , et al. The microbiome and hepatobiliary-pancreatic cancers[J]. Cancer Lett, 2017,402:9-15. DOI: 10.1016/j.canlet.2017.05.001.
|